Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer

OBJECTIVE: To evaluate the safety and efficacy of cabozantinib combined with docetaxel. PATIENTS AND METHODS: This was a phase 1/2 multicentre study in patients with metastatic castration-resistant prostate cancer (mCRPC). Docetaxel (75 mg/m(2) every 3 weeks with daily prednisone 10 mg) was combined...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:BJU Int
Main Authors: Madan, Ravi A., Karzai, Fatima H., Harthy, Munjid Al, Petrylak, Daniel P., Kim, Joseph W., Arlen, Philip M., Rosner, Inger, Theoret, Marc R., Cordes, Lisa, Bilusic, Marijo, Peer, Cody J., Dawson, Nancy A., Couvillon, Anna, Hankin, Amy, Williams, Moniquea, Chun, Guin, Owens, Helen, Marte, Jennifer L., Lee, Min-Jung, Tomita, Yusuke, Yuno, Akira, Trepel, Jane B., Lee, Sunmin, Steinberg, Seth M., Gulley, James L., Figg, William D., Dahut, William L.
Formato: Artigo
Idioma:Inglês
Publicado: 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8265825/
https://ncbi.nlm.nih.gov/pubmed/32969563
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bju.15227
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares